Adilipoline™ (S-(2,3-bis(palmitoyloxy)- (2RS)propyl)- (R)-cysteinyl-(S)-seryl-(S)- lysyl- (S)-lysyl- (S)-lysyl- (S)-lysyl 4 -((6-amino-2- (butylamino)-8- hydroxy-9H- purin-9-yl) methyl) aniline) was generated by conjugation of an 8-hydroxyadenine moiety to the terminal acid function of Pam2CSK4, a TLR2 agonist.
Adilipoline™ is a good ligand for both TLR2 and TLR7. In vivo tumor studies have demonstrated that Adilipoline™ is a potent antitumor agent. Intratumoral injection of Adilipoline™ in established B16 tumors resulted in tumor regression.
However, in contrast to AdiFectin™ (CL347), no protection after tumor rechallenge was observed.
